Diabetes, particularly type 2 diabetes (T2DM), is associated with an increased risk of genitourinary infections (GUIs), urinary tract infections (UTIs), and genital infections (GIs). Individuals with T2DM are more prone to UTIs and recurrent UTIs compared to those without T2DM, likely due to hyperglycemia and other risk factors. SGLT-2 inhibitors, a class of antihyperglycemic agents, are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications are crucial for preventing long-term complications, including genitourinary manifestations of diabetes. The available data on the association between SGLT-2 inhibitors and genitourinary infections is more comprehensive than that with UTIs. Further research is needed to understand the mechanisms underlying this association. The epidemiology of UTIs in people with diabetes shows a higher incidence compared to the general population, with a rate ratio ranging from 1.5 to 10. The bacteriology of UTIs is similar in nondiabetic and diabetic women, with Escherichia coli being the predominant organism. However, the antibiotic sensitivity patterns of the organisms in the two groups were not significantly different. Klebsiella spp. in people with diabetes with nosocomial UTI showed an overall increase in antibiotic resistance. In a cohort study using Taiwan’s National Health Insurance (NHI) claim data, it was shown that diabetes may minimally increase the rate of urinary tract calculi (UTC) in men with diabetes. The pathogenesis of UTIs in people with diabetes includes reduced neutrophil function, T cell responses, and humoral immunity, leading to increased susceptibility to infections. SGLT-2 inhibitors inhibit the sodium-glucose co-transporter 2 in the kidney’s proximal convoluted tubule, resulting in glycosuria, which may increase the risk of UTIs.Diabetes, particularly type 2 diabetes (T2DM), is associated with an increased risk of genitourinary infections (GUIs), urinary tract infections (UTIs), and genital infections (GIs). Individuals with T2DM are more prone to UTIs and recurrent UTIs compared to those without T2DM, likely due to hyperglycemia and other risk factors. SGLT-2 inhibitors, a class of antihyperglycemic agents, are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications are crucial for preventing long-term complications, including genitourinary manifestations of diabetes. The available data on the association between SGLT-2 inhibitors and genitourinary infections is more comprehensive than that with UTIs. Further research is needed to understand the mechanisms underlying this association. The epidemiology of UTIs in people with diabetes shows a higher incidence compared to the general population, with a rate ratio ranging from 1.5 to 10. The bacteriology of UTIs is similar in nondiabetic and diabetic women, with Escherichia coli being the predominant organism. However, the antibiotic sensitivity patterns of the organisms in the two groups were not significantly different. Klebsiella spp. in people with diabetes with nosocomial UTI showed an overall increase in antibiotic resistance. In a cohort study using Taiwan’s National Health Insurance (NHI) claim data, it was shown that diabetes may minimally increase the rate of urinary tract calculi (UTC) in men with diabetes. The pathogenesis of UTIs in people with diabetes includes reduced neutrophil function, T cell responses, and humoral immunity, leading to increased susceptibility to infections. SGLT-2 inhibitors inhibit the sodium-glucose co-transporter 2 in the kidney’s proximal convoluted tubule, resulting in glycosuria, which may increase the risk of UTIs.